Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARIAD Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: floWteiuQ who wrote (4407)	10/17/2016 10:17:03 PM
From: jaybe	Respond to of 4474

Just to clarify...neither of these types of ALL, T-cell and Precursor B-cell (PH negative) are directly related to pona's approved use in relapsed/refractory PH+ ALL, nor its potential "curative" use in frontline Ph+ ALL in combination with SOC chemo (HyperCVAD). Dr. Jabbour recently suggested Amgen's Blinctyo may be effectively combined with pona to enrich "cure" rate in Ph+ ALL, but note the frontline population for this indication weighs in at only ~3,000 patients worldwide. onclive.com